FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

LAZARUS ROCHELLE B
2. Issuer Name and Ticker or Trading Symbol

Merck & Co., Inc. [ MRK ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

OGILVY & MATHER, 636 11TH AVENUE
3. Date of Earliest Transaction (MM/DD/YYYY)

9/30/2019
(Street)

NEW YORK, NY 10036
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock                 1757  I  By Spouse 
Common Stock                 4594  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Phantom Stock   (1) 9/30/2019    A     341.5301       (2)  (2) Common Stock  341.5301  $84.18  85739.5121 (3) D   

Explanation of Responses:
(1)  1-for-1
(2)  Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.
(3)  Holdings include shares acquired in dividend reinvestment transactions.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
LAZARUS ROCHELLE B
OGILVY & MATHER
636 11TH AVENUE
NEW YORK, NY 10036
X



Signatures
/s/ Faye C. Brown as Attorney-in-Fact for Rochelle B. Lazarus 10/2/2019
**Signature of Reporting Person Date


Merck (NYSE:MRK)
Historical Stock Chart
Von Feb 2024 bis Mär 2024 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
Von Mär 2023 bis Mär 2024 Click Here for more Merck Charts.

News Merck & Co., Inc.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
Donnerstag 28 März 2024 (4 Stunden vor) • Business Wire
GameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More News
Mittwoch 27 März 2024 (1 Tag vor) • IH Market News
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
Dienstag 26 März 2024 (2 Tage vor) • Business Wire
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
Donnerstag 21 März 2024 (1 Woche vor) • Business Wire
Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
Dienstag 19 März 2024 (1 Woche vor) • Business Wire
FarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring Platform
Freitag 15 März 2024 (2 Wochen vor) • PR Newswire (US)
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
Freitag 15 März 2024 (2 Wochen vor) • Business Wire
Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9
Mittwoch 13 März 2024 (2 Wochen vor) • Business Wire
Merck Completes Acquisition of Harpoon Therapeutics, Inc.
Montag 11 März 2024 (2 Wochen vor) • Business Wire
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
Mittwoch 6 März 2024 (3 Wochen vor) • Business Wire
Futures Pointing To Continued Weakness On Wall Street
Dienstag 5 März 2024 (3 Wochen vor) • IH Market News
Merck to Participate in the Barclays 26th Annual Global Healthcare Conference
Dienstag 5 März 2024 (3 Wochen vor) • Business Wire